题名 | A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making |
作者 | |
发表日期 | 2023-01-13 |
发表期刊 | ANNALS OF TRANSLATIONAL MEDICINE 影响因子和分区 |
语种 | 英语 |
原始文献类型 | Article ; Early Access |
关键词 | Nomogram transarterial chemoembolization (TACE) hepatocellular carcinoma (HCC) |
其他关键词 | TACE ; SORAFENIB ; MRECIST |
摘要 | Background: There is still no standardized policy regarding how to identify patients who are not benefiting from transarterial chemoembolization (TACE). We aimed to establish and validate a nomogram model to predict the survival rate of hepatocellular carcinoma (HCC) patients after TACE.Methods: A total of 578 HCC patients undergoing initial TACE at the First Affiliated Hospital of Wenzhou Medical University were retrospectively recruited to the study. The patients were randomly divided into 2 cohorts: a training cohort (n=405) and a validation cohort (n=173). To develop the nomogram, Cox regression analyses were used to identify independent risk factors. The performances of the nomogram were assessed by concordance index (C-index), calibration curves, and decision curve analysis (DCA), and were compared to 4 developed prognostic models.Results: We used 5 independent risk factors including postoperative albumin-bilirubin (ALBI) grade, tumor diameter, number of tumors, portal vein invasion, and tumor response to develop the nomogram. Calibration curves showed consistency between the nomogram and the actual observation. The C-index of the nomogram was 0.753 [95% confidence interval (CI): 0.722, 0.784], which was higher than the other prognostic models (P<0.001). The DCA showed that the nomogram had the highest net benefit among the models. According to predicted survival risk, the nomogram could divide patients into 3 groups (P<0.001). All the results were verified in the validation cohort.Conclusions: This study developed and validated a nomogram model for HCC patients undergoing TACE, which could predict the survival rate and provide support for further treatment strategies. |
资助项目 | National Natural Science Foundation of China [81972233]; Major Scientific and Technological Innovation Project of Wenzhou Science and Technology Bureau [ZY2021009] |
出版者 | AME PUBLISHING COMPANY |
ISSN | 2305-5839 |
EISSN | 2305-5847 |
卷号 | 11期号:2 |
DOI | 10.21037/atm-22-6513 |
页数 | 13 |
WOS类目 | Oncology ; Medicine, Research & Experimental |
WOS研究方向 | Oncology ; Research & Experimental Medicine |
WOS记录号 | WOS:000917019000001 |
收录类别 | SCIE ; PUBMED |
在线发表日期 | 2023-01 |
URL | 查看原文 |
PubMed ID | 36819596 |
通讯作者地址 | [Xia, Jinglin]Wenzhou Med Univ, Affiliated Hosp 1, Key Lab Diag & Treatment Severe Hepatopancreat Dis, Wenzhou 325000, Peoples R China. |
引用统计 | |
文献类型 | 期刊论文 |
条目标识符 | https://kms.wmu.edu.cn/handle/3ETUA0LF/173052 |
专题 | 附属第一医院 第一临床医学院(信息与工程学院)、附属第一医院_影像医学与核医学_介入科 |
通讯作者 | Xia, Jinglin |
作者单位 | 1.Wenzhou Med Univ, Affiliated Hosp 1, Key Lab Diag & Treatment Severe Hepatopancreat Dis, Wenzhou, Peoples R China; 2.Wenzhou Med Univ, Affiliated Hosp 1, Dept Intervent Radiol, Wenzhou, Peoples R China; 3.Fudan Univ, Zhongshan Hosp, Liver Canc Inst, Shanghai, Peoples R China; 4.Wenzhou Med Univ, Affiliated Hosp 1, Key Lab Diag & Treatment Severe Hepatopancreat Dis, Wenzhou 325000, Peoples R China |
第一作者单位 | 附属第一医院 |
通讯作者单位 | 附属第一医院 |
第一作者的第一单位 | 附属第一医院 |
推荐引用方式 GB/T 7714 | Li, Jie,Li, Chengjun,Zhu, Guoqing,et al. A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making[J]. ANNALS OF TRANSLATIONAL MEDICINE,2023,11(2). |
APA | Li, Jie., Li, Chengjun., Zhu, Guoqing., Yang, Junhui., Zhang, Yunjie., ... & Xia, Jinglin. (2023). A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making. ANNALS OF TRANSLATIONAL MEDICINE, 11(2). |
MLA | Li, Jie,et al."A novel nomogram to predict survival of patients with hepatocellular carcinoma after transarterial chemoembolization: a tool for retreatment decision making".ANNALS OF TRANSLATIONAL MEDICINE 11.2(2023). |
条目包含的文件 | 条目无相关文件。 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论